Expand all sections

Pimavanserin

Nuplazid

Extended indication Hallucinations and delusions associated with Parkinson's disease.
Therapeutic value Possible equal value

Product

Active substance Pimavanserin
Domain Neurological disorders
Main indication Parkinson's
Extended indication Hallucinations and delusions associated with Parkinson's disease.
Proprietary name Nuplazid
Manufacturer Acadia
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Extramural (GVS)
Additional remarks Werkingsmechanisme: 'Selective serotonin 5-HT2A inverse agonist'. Hierbij is de claim dat het geen effect heeft op D2-receporen.

Registration

Registration route Centralised (EMA)
Orphan drug No
Additional remarks Nuplazid is in april 2016 geregistreerd door FDA.

Therapeutic value

Current treatment options Clozapine of Quetiapine.
Therapeutic value Possible equal value
Substantiation Het is nog onduidelijk wat de toegevoegde waarde is t.o.v. Clozapine en Quetiapine. Een mogelijke gelijke waarde lijkt te veronderstellen met de huidige informatie
Duration of treatment Not found
Frequency of administration 1 times a day
Dosage per administration 34 mg
References Cummings J. et al. Lancet. 2014 Feb 8;383(9916):533-40. doi: 10.1016/S0140-6736(13)62106-6. Bozymski KM et al.Ann Pharmacother. 2017 Jun;51(6):479-487. doi: 10.1177/1060028017693029. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf, DUITS JH. et al.Tijdschr Psychiatr. 2017;59(9):528-536.

Expected patient volume per year

Additional remarks Verwachting aantal patiënten honderden / duizenden.

Expected cost per patient per year

Cost 25,000.00
References GoodRx
Additional remarks Gemiddeld in de VS $2,478.21 voor 60 tabletten van 17mg. $29.738,52 p.p.p.j.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

Off label use Yes
Indications off label use Off-label: Dementie.

Indication extension

Indication extension Yes
Indication extensions Indicatie-uitbreiding: andere psychose gerelateerd aan dementie of neuropsychiatrische beelden
References Clinicaltrials.gov.

Other information

There is currently no futher information available.